Objective: Preexisting diabetes mellitus (DM) and post-transplant diabetes mellitus (PTDM) impact outcomes post solid organ transplantation (SOT). Benefits of tirzepatide are well studied in DM but not in patients after SOT. This study describes safety and efficacy of tirzepatide in SOT.

Methods: Retrospective data was collected on 16 SOT patients with DM/PTDM on insulin, oral agents or both after initiation of tirzepatide for 6 months. [Table 1] Changes from baseline in A1C and weight (efficacy), and eGFR and tacrolimus levels (safety) were assessed.

Results: From baseline to 6 months, mean A1C reduced by 14.8% (-1.3%) and weight by 6.9% (-5.4 kg), but were not statistically significant. eGFR and tacrolimus levels were unchanged. [Table 2]

Conclusion: Tirzepatide may be a safe and effective drug in SOT patients. Larger studies are warranted.

graphic
View largeDownload slide
graphic
View largeDownload slide
Disclosure

S. Dowlatshahi: None. B. Patham: None. A. Kansara: None. A.W. Rogers: None. A.R. Sadhu: Advisory Panel; Abbott Diagnostics.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.